AbbVie’s Drug ABT-414 Has Been Granted Orphan Drug Status by Both the FDA and EMA for the Treatment of Glioblastoma Multiforme
The pharmaceutical company AbbVie has been granted coveted orphan drug status by both the European Medicines Agency and the US Food and Drug Administration for its drug ABT-414 for the treatment of glioblastoma multiforme.
Glioblastoma multiforme is one of the most common types of brain tumours that afflicts people. With very low rates of survival of under 10%, the pressure to develop a drug to remedy the condition is high.
The drug will now move into phase 2 trials, whilst receiving marketing and development incentives from the government as a result of its orphan status.